TAIPEI and SAN DIEGO, Sept. 17, 2024 /PRNewswire/ — Senhwa Biosciences, Inc. (TPEx: 6492), , a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that an Investigational […]
– Designación de terapia innovadora para los comprimidos sublinguales de Sanbexin otorgada por la Administración de Alimentos y Medicamentos de Estados Unidos NANJING, China, 16 de septiembre de 2024 /PRNewswire/ — El 2 de septiembre […]
The first and only dual-acting interleukin-23 inhibitor approved in active ulcerative colitis, TREMFYA® showed highly statistically significant rates of endoscopic remission at one year in the pivotal QUASAR program1,2,3,4,5 TREMFYA® is now approved for the treatment of […]
Novavax expects pre-filled syringes will be broadly available in thousands of locations across the U.S. Novavax’s vaccine is the only protein-based option available in the U.S. for use in individuals aged 12 and older to […]